S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
Log in
LON:ERGO

Ergomed plc (ERGO.L) Share Forecast, Price & News

GBX 1,090.50
-9.50 (-0.86 %)
(As of 01/27/2021 10:37 AM ET)
Add
Compare
Today's Range
1,060
Now: GBX 1,090.50
1,100
50-Day Range
945
MA: GBX 1,034.50
1,200
52-Week Range
258
Now: GBX 1,090.50
1,230
Volume176,555 shs
Average Volume135,259 shs
Market Capitalization£531.29 million
P/E Ratio87.24
Dividend YieldN/A
BetaN/A
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom and Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, neurology, and CNS, as well as develops orphan drugs. The company also provides site support services. Ergomed plc was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Ergomed plc (ERGO.L) logo

MarketRank

Overall MarketRank

0.62 out of 5 stars

Analyst Opinion: 0.0Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1483-503205
Employees850
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£73.46 million
Cash FlowGBX 65.21 per share
Book ValueGBX 90.60 per share

Profitability

Miscellaneous

Market Cap£531.29 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 1,090.50
-9.50 (-0.86 %)
(As of 01/27/2021 10:37 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ERGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ERGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ergomed plc (ERGO.L) (LON:ERGO) Frequently Asked Questions

How has Ergomed plc (ERGO.L)'s stock been impacted by COVID-19 (Coronavirus)?

Ergomed plc (ERGO.L)'s stock was trading at GBX 392 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ERGO shares have increased by 180.4% and is now trading at GBX 1,099.20.
View which stocks have been most impacted by COVID-19
.

What stocks does MarketBeat like better than Ergomed plc (ERGO.L)?

Wall Street analysts have given Ergomed plc (ERGO.L) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ergomed plc (ERGO.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Ergomed plc (ERGO.L)'s earnings last quarter?

Ergomed plc (ERGO.L) (LON:ERGO) announced its quarterly earnings data on Monday, September, 18th. The company reported $1.20 EPS for the quarter. The business had revenue of $22.91 million for the quarter.
View Ergomed plc (ERGO.L)'s earnings history
.

Who are some of Ergomed plc (ERGO.L)'s key competitors?

What other stocks do shareholders of Ergomed plc (ERGO.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ergomed plc (ERGO.L) investors own include Dicerna Pharmaceuticals (DRNA), AbbVie (ABBV), Axsome Therapeutics (AXSM), FuelCell Energy (FCEL), NIO (NIO), Science Applications International (SAIC), Northern Dynasty Minerals (NAK), Tilray (TLRY), Agilent Technologies (A) and American Express (AXP).

Who are Ergomed plc (ERGO.L)'s key executives?

Ergomed plc (ERGO.L)'s management team includes the following people:
  • Dr. Miroslav Reljanovic, Founder & Exec. Chairman (Age 61, Pay $214.16k)
  • Mr. Richard T. Barfield, CFO & Exec. Director (Age 62, Pay $264.82k)
  • Ms. Sanja Juric, Gen. Counsel & Company Sec.
  • Ms. Dora Alvarado, Global Head of HR
  • Dr. Michael Forstner, Head of Risk Management & Pharmacoepidemiology
  • Ms. Roy Ovel, Chief Commercial Officer
  • Dr. Gordana Tonkovic, Pres of CRO
  • Mr. Jonathan West, Pres of PrimeVigilance

What is Ergomed plc (ERGO.L)'s stock symbol?

Ergomed plc (ERGO.L) trades on the London Stock Exchange (LON) under the ticker symbol "ERGO."

How do I buy shares of Ergomed plc (ERGO.L)?

Shares of ERGO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Ergomed plc (ERGO.L)'s stock price today?

One share of ERGO stock can currently be purchased for approximately GBX 1,099.20.

How big of a company is Ergomed plc (ERGO.L)?

Ergomed plc (ERGO.L) has a market capitalization of £535.52 million and generates £73.46 million in revenue each year. Ergomed plc (ERGO.L) employs 850 workers across the globe.

What is Ergomed plc (ERGO.L)'s official website?

The official website for Ergomed plc (ERGO.L) is www.ergomedplc.com.

How can I contact Ergomed plc (ERGO.L)?

Ergomed plc (ERGO.L)'s mailing address is 26-24 Frederick Sanger Road, GUILDFORD, GU2 7YD, United Kingdom. The company can be reached via phone at +44-1483-503205.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.